Moleculin Biotech Announces $9.3M Public Offering of Stock & Warrants

What Happened

• Moleculin Biotech, Inc. (MBRX) announced a public offering arranged with Roth Capital Partners that closed on August 3, 2026. The offering sold 12,376,667 shares of common stock (or pre‑funded warrants in lieu thereof) together with Series I common stock purchase warrants exercisable for up to 37,130,001 shares, at a combined public price of $0.75 per share (or pre‑funded warrant) plus accompanying warrant. The gross proceeds to the company were approximately $9.3 million before fees and expenses. The offering was made under an S-1 registration statement declared effective July 31, 2026.

Key Details

• Closing date: August 3, 2026; Registration Statement Form S-1 declared effective July 31, 2026.
• Securities: 12,376,667 common shares (or pre‑funded warrants) and Series I warrants to buy up to 37,130,001 shares; combined public price $0.75.
• Warrant economics: Pre‑funded warrants exercisable for one share at $0.001; common warrants exercisable at $0.75, expire five years after initial exercise availability; cashless exercise only if no registration/prospectus availability.
• Ownership limits and anti‑dilution: Holder exercise limited to avoid >4.99% ownership (holder may elect up to 9.99%); common warrants include price‑adjustment protection down to a floor of $0.21 in certain future issuances.
• Fees and restrictions: Placement agent fee to Roth of 6.5% of gross proceeds; Maxim Group advisor fee 1.0%; directors/officers subject to 60‑day lock‑up; company agreed to a 45‑day limited issuance blackout and restrictions on certain variable‑rate transactions for 180 days (with some exceptions and ATM sales allowed after day 46).
• Use of proceeds: Company intends to use net proceeds to advance Annamycin through clinical development and for working capital.

Why It Matters

• The transaction provides near‑term cash (~$9.3M gross) to fund clinical development of Annamycin and general operations, which can extend the company’s runway.
• The issuance and associated warrants increase potential dilution for existing shareholders (current shares sold plus up to 37.1M shares underlying warrants). Warrant exercise terms, ownership caps, and anti‑dilution protections affect when and how much additional dilution may occur.
• Placement fees and expenses reduce net proceeds; lock‑ups and blackout periods limit insider selling and the company’s ability to issue additional equity for a defined period.

Keywords: public offering, warrants, dilution, proceeds, Annamycin, Roth Capital, placement agent.